To the best of our knowledge, no studies have evaluated the effects of pegvisomant in preclinical or clinical models of HCC, but the GHR expression and GH effect on HCC permit to hypothesize a role of pegvisomant in this tumour. This evidence concerns the gene GH1 and neoplasm.